NKG2A discriminates natural killer cells with a suppressed phenotype in pediatric acute leukemia
- PMID: 37738462
- DOI: 10.1093/jleuko/qiad112
NKG2A discriminates natural killer cells with a suppressed phenotype in pediatric acute leukemia
Abstract
Natural killer (NK) cells are important for early tumor immune surveillance. In patients with hematological cancers, NK cells are generally functional deficient and display dysregulations in their receptor repertoires. Acute leukemia is the most common cancer in children, and we here performed a comparative phenotypic profiling of NK cells from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients to identify aberrant NK cell phenotypes. NK cell phenotypes, maturation, and function were analyzed in matched bone marrow and blood NK cells from BCP-ALL patients at diagnosis, during treatment, and at end of treatment and compared with age-matched pediatric control subjects. Expression of several markers were skewed in patients, but with large interindividual variations. Undertaking a multiparameter approach, we found that high expression levels of NKG2A was the single predominant marker distinguishing NK cells in BCP-ALL patients compared with healthy control subjects. Moreover, naïve CD57-NKG2A NK cells dominated in BCP-ALL patients at diagnosis. Further, we found dysregulated expression of the activating receptor DNAM-1 in resident bone marrow CXCR6+ NK cells. CXCR6+ NK cells lacking DNAM-1 expressed NKG2A and had a tendency for lower degranulation activity. In conclusion, high expression of NKG2A dominates NK cell phenotypes from pediatric BCP-ALL patients, indicating that NKG2A could be targeted in therapies for this patient group.
Keywords: BCP-ALL; CXCR6; DNAM-1; blood; bone marrow.
© The Author(s) 2023. Published by Oxford University Press on behalf of Society for Leukocyte Biology.
Conflict of interest statement
Conflict of interest statement. The authors declare no conflict of interest.
Similar articles
-
Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.Arch Med Res. 2016 Jan;47(1):55-64. doi: 10.1016/j.arcmed.2016.02.001. Epub 2016 Feb 12. Arch Med Res. 2016. PMID: 26876298
-
Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56-CD16+ Natural Killer Cell Subset Is Associated with Natural Killer Cell Dysfunction in Chronic HIV-1 Clade C Infection.AIDS Res Hum Retroviruses. 2017 Dec;33(12):1205-1213. doi: 10.1089/AID.2017.0095. Epub 2017 Sep 21. AIDS Res Hum Retroviruses. 2017. PMID: 28810810
-
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.Front Immunol. 2019 Jan 17;9:3152. doi: 10.3389/fimmu.2018.03152. eCollection 2018. Front Immunol. 2019. PMID: 30705677 Free PMC article.
-
Gene expression analysis of activating and inhibitory receptors of natural killer cells in patients with acute myeloblastic leukemia.Adv Med Sci. 2020 Sep;65(2):354-360. doi: 10.1016/j.advms.2020.05.007. Epub 2020 Jun 24. Adv Med Sci. 2020. PMID: 32592956
-
Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.J Leukoc Biol. 2019 Jun;105(6):1243-1251. doi: 10.1002/JLB.MR0718-300R. Epub 2019 Jan 15. J Leukoc Biol. 2019. PMID: 30645023 Review.
Cited by
-
Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.J Immunother Cancer. 2024 Oct 31;12(10):e009934. doi: 10.1136/jitc-2024-009934. J Immunother Cancer. 2024. PMID: 39486805 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical